Where are CSL (ASX:CSL) shares headed in 2022?

Australia's largest healthcare company just pulled off the nation's biggest capital raise of all time. Now what?

| More on:
The back of a man standing in front of two roads going in different directions.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a wild ride for CSL Limited (ASX: CSL) shareholders this year.

Before the market opened on Friday, the biotechnology stock had only changed 2.4% upwards in all of 2021 to trade at $291.83. 

But along the way, investors had to hold on for dear life through a 52-week high of $319.78 and a low of $242.

So where will CSL shares head in 2022?

Next 3 to 6 months are critical for CSL

To finish the year, CSL raised $6.3 billion of capital to fund its acquisition of Swiss company Vifor Pharma AG (SWX: VIFN).

According to Redpoint Investment Management chief Max Cappetta, it was "the single largest primary raising in Australian history" and allowed the takeover to complete at an 8% discount to market price.

"On paper, the merits of the transaction are for an immediate uplift in EPS [earnings per share] for the group, however, there are some uncertainties related to patent litigation at Vifor," he told The Motley Fool.

"This acquisition presents a new and valuable growth opportunity for a company which has prided itself on exemplary global growth over the past two decades."

Currently, Cappetta's team estimates that the CSL share price is at a "slight premium" to what they think is fair value.

"The next 3 to 6 months will be critical for the company to show that this acquisition will deliver the growth that the company needs to reaffirm its long-term share price performance," he said.

"All eyes will be on the management discussion at their mid-year result in February."

'Pipeline of lucrative products under development'

Analysts at Citi are perhaps more bullish on CSL's share price.

Last week they slapped a "buy" rating on the stock with a price target of $340, which is a 16.5% upside to the current level.

As well as the Vifor acquisition giving the business additional capability in kidney disease and iron deficiency treatments, CSL's plasma collection operations should pick up as the US moves past COVID-19 restrictions.

"But it doesn't stop there," reported The Motley Fool's James Mickleboro.

"Thanks to its ~US$1 billion spend on R&D annually, CSL has a pipeline of lucrative products under development to drive its future growth."

Motley Fool contributor Tony Yoo owns CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »